XML 59 R37.htm IDEA: XBRL DOCUMENT
v3.24.3

Fair Value Measurements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Fair Value Disclosures [Abstract] |
Summary of assets and liabilities recorded at fair value | The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:
|  | Fair Value Measurements on a Recurring Basis
|  | As of September 30, 2024
(In millions) |  | Total |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |  |
Cash equivalents |  | $ | 802.4 |  |  | $ | — |  |  | $ | 802.4 |  |  | $ | — |
Marketable equity securities |  | 304.7 |  |  | 304.7 |  |  | — |  |  | — |
Other current assets: |  |  |  |  |  |  |  |
Derivative contracts |  | 6.0 |  |  | — |  |  | 6.0 |  |  | — |
Other non-current assets: |  |  |  |  |  |  |  |
Plan assets for deferred compensation |  | 42.8 |  |  | — |  |  | 42.8 |  |  | — |
Derivative contracts |  | 0.1 |  |  | — |  |  | 0.1 |  |  | — |
Total |  | $ | 1,156.0 |  |  | $ | 304.7 |  |  | $ | 851.3 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |
Other current liabilities: |  |  |  |  |  |  |  |
Derivative contracts |  | $ | 31.6 |  |  | $ | — |  |  | $ | 31.6 |  |  | $ | — |
Contingent consideration obligations |  | 287.1 |  |  | — |  |  | — |  |  | 287.1 |
Other non-current liabilities: |  |  |  |  |  |  |  |
Derivative contracts |  | 2.4 |  |  | — |  |  | 2.4 |  |  | — |
Contingent consideration obligations |  | 221.8 |  |  | — |  |  | — |  |  | 221.8 |
Total |  | $ | 542.9 |  |  | $ | — |  |  | $ | 34.0 |  |  | $ | 508.9 |
|  | Fair Value Measurements on a Recurring Basis
|  | As of December 31, 2023
(In millions) |  | Total |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Assets: |  |  |  |  |  |  |  |
Cash equivalents |  | $ | 610.7 |  |  | $ | — |  |  | $ | 610.7 |  |  | $ | — |
Marketable equity securities |  | 416.8 |  |  | 416.8 |  |  | — |  |  | — |
Other current assets: |  |  |  |  |  |  |  |
Receivable from Samsung BioLogics(1) |  | 430.0 |  |  | — |  |  | — |  |  | 430.0 |
Derivative contracts |  | 11.9 |  |  | — |  |  | 11.9 |  |  | — |
Other non-current assets: |  |  |  |  |  |  |  |
Plan assets for deferred compensation |  | 37.5 |  |  | — |  |  | 37.5 |  |  | — |
Total |  | $ | 1,506.9 |  |  | $ | 416.8 |  |  | $ | 660.1 |  |  | $ | 430.0 |
Liabilities: |  |  |  |  |  |  |  |
Derivative contracts |  | $ | 31.6 |  |  | $ | — |  |  | $ | 31.6 |  |  | $ | — |
Total |  | $ | 31.6 |  |  | $ | — |  |  | $ | 31.6 |  |  | $ | — |
(1) Represents the fair value of the second deferred payment due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 3, Dispositions, to these condensed consolidated financial statements.
Fair Value Measurement Inputs and Valuation Techniques | The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:
|  | Quantitative Information about Level 3 Fair Value Measurements
|  | As of September 30, 2024
(In millions) |  | Fair Value |  | Valuation Technique |  | Significant Unobservable Input(s) |  | Range |  | Weighted Average
Liabilities: |  |  |  |  |  |  |  |  |  |
Contingent consideration obligations |  | $ | 508.9 |  |  | Discounted cash flow |  | Discount rate |  | 5.4% - 5.8% |  | 5.6 | %
|  |  |  |  |  | Expected timing of achievement of development milestones |  | 2025 - 2030 |  | — |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation | The following table provides a roll forward of the fair value of our contingent consideration obligation, which was classified as a Level 3 measurement:
(In millions) |  | For the Three and Nine Months Ended September 30, 2024 |  |  |  |  |  |
Fair value, beginning of period |  | $ | — |  |  |  |  |  |  |
Contingent consideration resulting from HI-Bio acquisition |  | 485.1 |  |  |  |  |  |  |
Changes in fair value |  | 23.8 |  |  |  |  |  |  |
Fair value, end of period |  | $ | 508.9 |  |  |  |  |  |  |
Summary of fair and carrying value of debt instruments | The fair and carrying values of our debt instruments, which are Level 2 liabilities, are summarized as follows:
|  | As of September 30, 2024 |  | As of December 31, 2023
(In millions) |  | Fair Value |  | Carrying Value |  | Fair Value |  | Carrying Value
Current portion: |  |  |  |  |  |  |  |
2023 Term Loan 364-day tranche |  | $ | — |  |  | $ | — |  |  | $ | 150.0 |  |  | $ | 150.0 |
4.050% Senior Notes due September 15, 2025 |  | 1,739.9 |  |  | 1,748.1 |  |  | — |  |  | — |
Current portion of notes payable and term loan |  | 1,739.9 |  |  | 1,748.1 |  |  | 150.0 |  |  | 150.0 |
Non-current portion: |  |  |  |  |  |  |  |
2023 Term Loan three-year tranche |  | — |  |  | — |  |  | 500.0 |  |  | 500.0 |
4.050% Senior Notes due September 15, 2025 |  | — |  |  | — |  |  | 1,721.5 |  |  | 1,746.6 |
2.250% Senior Notes due May 1, 2030 |  | 1,339.4 |  |  | 1,494.5 |  |  | 1,279.3 |  |  | 1,493.8 |
5.200% Senior Notes due September 15, 2045 |  | 1,079.2 |  |  | 1,101.0 |  |  | 1,089.7 |  |  | 1,100.7 |
3.150% Senior Notes due May 1, 2050 |  | 1,034.1 |  |  | 1,474.8 |  |  | 1,049.0 |  |  | 1,474.3 |
3.250% Senior Notes due February 15, 2051 |  | 490.9 |  |  | 475.5 |  |  | 498.2 |  |  | 472.8 |
Non-current portion of notes payable and term loan |  | 3,943.6 |  |  | 4,545.8 |  |  | 6,137.7 |  |  | 6,788.2 |
Total notes payable and term loan |  | $ | 5,683.5 |  |  | $ | 6,293.9 |  |  | $ | 6,287.7 |  |  | $ | 6,938.2 |
In connection with our acquisition of Reata we drew $1.0 billion from our 2023 Term Loan, comprised of a $500.0 million floating rate 364-day tranche and a $500.0 million floating rate three-year tranche. As of September 30, 2024, our 2023 Term Loan was repaid in full. For additional information on our 2023 Term Loan, please read Note 13, Indebtedness, to these condensed consolidated financial statements.

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration